Investor Presentaiton

10 1. Extensive Manufacturing Facility Located in Iceland Key Features Capacity and Scalability Flexible Capabilities Externally Validated Quality alvotech Technology & Capabilities Approximately ~280,000ft² facility (inclusive of ongoing expansion) with existing 4-wall drug substance capacity expected to support pipeline through 2030 (1) • Commercial product manufacturing initiated, with inventory build underway Differentiated capabilities including CHO and SP2/0 host cell lines Single use bioreactors for use with fed batch or perfusion processes Aseptic fill/finish capabilities 3 successful IMA/EMA inspections with clinical and commercial licenses issued 4 commercial partner audits successfully completed Conveniently situated between the U.S. and Europe Intentionally Located Powered by renewable energy with access to abundant clean and hot water Operates in a "patent-light" zone Includes 140,000ft² ongoing capacity expansion projects expected to be completed in early 2024 - costs for this are included in Alvotech's financial guidance © ALVOTECH. ALL RIGHTS RESERVED

View entire presentation